Integrating biomarkers in colorectal cancer trials in the West and China

摘要: The discovery of biomarkers that provide information on drug efficacy is recognized as essential for successful and cost-effective treatment cancer. However, biomarker difficult, requires multiple independent studies to identify a target serves suitable predictor ensure appropriate validation. Clinical trials are performed, sometimes sequentially, in Europe, the USA or Asia, often similar their design, part owing regulatory, marketing, safety considerations. We believe some these offer additional unique opportunities There hurdles overcome, such homogenous tissue acquisition analysis, defining aligning hypotheses across trials, need adapt sample sizes trial designs. Nevertheless, we collaborative engagement academic, regulatory pharmaceutical community can go long way addressing issues producing more-rapid results field personalized medicine. In this Perspectives, describe our views current fragmented approach validation relevant run within own regions-that is, China, USA-and hope article base further reflection.